Form 4 for HCWB HCW Biologics Inc.
Accepted 2023-11-20 00:00:00 ET · period of report 2023-11-17 · accession 0001209191-23-056086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-20 | 2023-11-17 | HCWB | Rhode Peter | See Remarks | M - OptEx | $0.14 | +15.0K | 63.5K | +31% | +$2,100 |
| D | 2023-11-20 | 2023-11-17 | HCWB | Rhode Peter | See Remarks | M - OptEx | $0.00 | -15.0K | 36.4K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-17 | M | A | 15,000 | $0.14 | 63,500 | D | — | — | |
| 2 | Derivative | Stock Option Grant (Right to Buy) | 2023-11-17 | M | D | 15,000 | $0.00 | 36,427 | D | $0.14 · — to 2029-12-19 | 15,000 Common Stock | (F1) These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date. |